Phase 3 Readout~month

Phase 3 Topline: Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (

Indication
Stage IV Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Advanced Lung Non-Squamous Non-Small Cell Carcinoma

Other upcoming events for AMRX

Phase 3 ReadoutPhase 3 Topline: Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth F
Phase 3 ReadoutPhase 3 Topline: A Randomized Phase III Trial of Carboplatin, Paclitaxel, Pembrolizumab Versus Carboplatin, Paclitaxe

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib ( — AMRX Phase 3 Readout | BioSniper